VivoSeq
Oncology

Small Cell Lung Cancer ( SCLC )

11

Pipeline Programs↗

6

Active Trials↗

9

Companies Involved↗

Small Cell Lung Cancer ( SCLC ) is an emerging landscape with 11 programs across 9 companies. The most active players are Avyxa, Boehringer Ingelheim, Roche. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

22/100

Mech. Concentration

40/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avyxa

2 programs

Phase 3Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 3Roche logo

Roche

2 programs

Phase 3Pfizer logo

Pfizer

2 programs

PreclinicalP

Phanes Therapeutics

1 program

PreclinicalAstraZeneca logo

AstraZeneca

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

91%

Small molecule

10 of 11 classified programs — the dominant modality here.

9%ALL OTHERSMonoclonal antibody19%

Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 93% of 14 pipeline programs.

Analysis

Trial Status

6

clinical trials

Recruiting5 · 83%
Not yet recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)
Recruiting·PPhanes Therapeutics·Preclinical·NCT05652686·203 enrolled
A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER
Recruiting·Pfizer logoPfizer·Preclinical·NCT07226999·550 enrolled
DAREON ® -Lung-1: A Phase III Multi-center, Open-label, Randomised Trial of Intravenous Obrixtamig in Combination With Atezolizumab, Carboplatin, and Etoposide vs. Atezolizumab, Carboplatin, and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer
Recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 3·NCT07472517·670 enrolled
An Exploratory Phase II Study of Bemotuzumab Combined With Chemotherapy and Anlotinib as Induction Therapy, Followed by Bemotuzumab, Anlotinib, and Consolidative Thoracic Radiotherapy in Patients With Extensive-Stage Small Cell Lung Cancer
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07358676·25 enrolled
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
Recruiting·AAlliance Foundation Trials, LLC.·Phase 2·NCT07149363·65 enrolled
A Phase 1 First-In-Human Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of ML261, an Autologous Anti-DLL3 CAR + CARD11-PIK3R3 Fusion T Cell Therapy, in Participants With Relapsed/Refractory Small Cell Lung Cancer or Select Neuroendocrine Carcinomas
Not yet recruiting·MMoonlight Bio, Inc·Phase 1·NCT07488923·110 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)